Drug Profile
Glesatinib - Mirati Therapeutics
Alternative Names: MGCD-265Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator MethylGene
- Developer MethylGene; Mirati Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto-oncogene protein c-met inhibitors; RON protein inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Head and neck cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 04 Nov 2021 Mirati Therapeutics completes a phase-II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) (NCT02954991)
- 01 Jan 2019 Mirati Therapeutics completes a phase I trial in Non-small cell lung cancer, Head and neck cancer and other solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada, South Korea and USA (PO) (NCT00697632)